BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37289265)

  • 1. Treatment strategy for hepatocellular carcinoma recurrence in the transplant era: Focusing on the Japan criteria.
    Yoshiya S; Harada N; Toshima T; Toshida K; Kosai Y; Tomino T; Nagao Y; Kayashima H; Itoh S; Yoshizumi T
    Surg Today; 2024 Jan; 54(1):64-72. PubMed ID: 37289265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictor of outcome after living donor liver transplantation for patients with hepatocellular carcinoma beyond the Japan criteria.
    Yonemura Y; Yoshizumi T; Inokuchi S; Kosai-Fujimoto Y; Harada N; Itoh S; Toshima T; Takeishi K; Yoshiya S; Mori M
    Ann Gastroenterol Surg; 2020 Jul; 4(4):413-421. PubMed ID: 32724885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
    Lee KW; Yi NJ; Suh KS
    Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the outcomes of patients who underwent deceased-donor or living-donor liver transplantation after successful downstaging therapy.
    Lei J; Yan L; Wang W
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1340-6. PubMed ID: 23652915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-for-size grafts increase recurrence of hepatocellular carcinoma in liver transplantation beyond milan criteria.
    Lee EC; Kim SH; Shim JR; Park SJ
    Liver Transpl; 2018 Jan; 24(1):35-43. PubMed ID: 28885774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma.
    Na GH; Kim EY; Hong TH; You YK; Kim DG
    HPB (Oxford); 2016 Jan; 18(1):98-106. PubMed ID: 26776857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.
    Harimoto N; Shirabe K; Nakagawara H; Toshima T; Yamashita Y; Ikegami T; Yoshizumi T; Soejima Y; Ikeda T; Maehara Y
    Transplantation; 2013 Dec; 96(11):1008-12. PubMed ID: 24113512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation.
    Park MS; Lee KW; Suh SW; You T; Choi Y; Kim H; Hong G; Yi NJ; Kwon CH; Joh JW; Lee SK; Suh KS
    Transplantation; 2014 Jan; 97(1):71-7. PubMed ID: 24056623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.
    Choi HJ; Kim DG; Na GH; Han JH; Hong TH; You YK
    World J Gastroenterol; 2013 Aug; 19(29):4737-44. PubMed ID: 23922471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Living donor liver transplantation for hepatocellular carcinoma.
    Lee SG; Moon DB
    Recent Results Cancer Res; 2013; 190():165-79. PubMed ID: 22941020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.
    Na GH; Hong TH; You YK; Kim DG
    World J Gastroenterol; 2016 Jul; 22(25):5790-9. PubMed ID: 27433092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma.
    Harimoto N; Yoshida Y; Kurihara T; Takeishi K; Itoh S; Harada N; Tsujita E; Yamashita YI; Uchiyama H; Soejima Y; Ikegami T; Yoshizumi T; Kawanaka H; Ikeda T; Shirabe K; Saeki H; Oki E; Kimura Y; Maehara Y
    Transplant Proc; 2015 Apr; 47(3):703-4. PubMed ID: 25819732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort.
    Kulik LM; Fisher RA; Rodrigo DR; Brown RS; Freise CE; Shaked A; Everhart JE; Everson GT; Hong JC; Hayashi PH; Berg CL; Lok AS;
    Am J Transplant; 2012 Nov; 12(11):2997-3007. PubMed ID: 22994906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation.
    Xiao GQ; Song JL; Shen S; Yang JY; Yan LN
    World J Gastroenterol; 2014 Aug; 20(31):10953-9. PubMed ID: 25152599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis.
    Liang W; Wu L; Ling X; Schroder PM; Ju W; Wang D; Shang Y; Kong Y; Guo Z; He X
    Liver Transpl; 2012 Oct; 18(10):1226-36. PubMed ID: 22685095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence.
    Sandhu L; Sandroussi C; Guba M; Selzner M; Ghanekar A; Cattral MS; McGilvray ID; Levy G; Greig PD; Renner EL; Grant DR
    Liver Transpl; 2012 Mar; 18(3):315-22. PubMed ID: 22140013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of ABO-incompatibility on hepatocellular carcinoma recurrence after living donor liver transplantation.
    Kim SH; Lee EC; Na BG; Park SJ
    Eur J Surg Oncol; 2019 Feb; 45(2):180-186. PubMed ID: 30243467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Living donor liver transplantation for hepatocellular carcinoma: results of prospective patient selection by Kyushu University Criteria in 7 years.
    Uchiyama H; Itoh S; Yoshizumi T; Ikegami T; Harimoto N; Soejima Y; Harada N; Morita K; Toshima T; Motomura T; Maehara Y
    HPB (Oxford); 2017 Dec; 19(12):1082-1090. PubMed ID: 28888776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of living and deceased donor liver transplantation as a treatment for hepatocellular carcinoma.
    Ninomiya M; Shirabe K; Facciuto ME; Schwartz ME; Florman SS; Yoshizumi T; Harimoto N; Ikegami T; Uchiyama H; Maehara Y
    J Am Coll Surg; 2015 Mar; 220(3):297-304.e3. PubMed ID: 25617912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations.
    Hwang S; Lee SG; Joh JW; Suh KS; Kim DG
    Liver Transpl; 2005 Oct; 11(10):1265-72. PubMed ID: 16184545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.